Everence Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Everence Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$233K	Buy	+738	New	+$174K	0.01%	756
2024 Q4	–	Sell	-2,760	Closed	-$276K	–	941
2024 Q3	$276K	Buy	+2,760	New	+$278K	0.02%	625
2024 Q2	–	Sell	-2,760	Closed	-$202K	–	750
2024 Q1	$202K	Buy	+2,760	New	+$203K	0.01%	716
2023 Q2	–	Sell	-2,760	Closed	-$203K	–	736
2023 Q1	$203K	Buy	+2,760	New	+$196K	0.02%	678
2022 Q4	–	Sell	-4,424	Closed	-$238K	–	782
2022 Q3	$238K	Hold	4,424	–	–	0.02%	598
2022 Q2	$246K	Hold	4,424	–	–	0.02%	579
2022 Q1	$310K	Hold	4,424	–	–	0.02%	549
2021 Q4	$426K	Buy	+4,424	New	+$409K	0.03%	474
2018 Q4	–	Sell	-2,741	Closed	-$469K	–	436
2018 Q3	$469K	Hold	2,741	–	–	0.09%	235
2018 Q2	$354K	Buy	2,741 +705	+35%	+$78.7K	0.07%	279
2018 Q1	$210K	Buy	+2,036	New	+$201K	0.05%	385

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Everence Capital Management's LGND Position: Q2 2026 in Review

Everence Capital Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 738 shares worth $233K. The stake represents 0.01% of the portfolio and ranks #756 among its holdings. This is a return to the name: Everence Capital Management previously reported a position in LGND as recently as Q3 2024.

Everence Capital Management first reported a position in LGND in Q1 2018 and has held it in 11 quarters since. The position peaked at $469K in Q3 2018. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Everence Capital Management held 738 shares of Ligand Pharmaceuticals worth $233K as of Q2 2026.
Ligand Pharmaceuticals was a new Everence Capital Management position in Q2 2026.
Ligand Pharmaceuticals made up 0.01% of Everence Capital Management's portfolio in Q2 2026, its #756 holding.
Everence Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2018 and has held it in 11 quarters since.
Everence Capital Management's Ligand Pharmaceuticals position peaked at $469K in Q3 2018.
416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.